Role of interaction of mGlu2 and 5-HT2A receptors in antipsychotic effects
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of interaction of mGlu2 and 5-HT2A receptors in antipsychotic effects
Authors
Keywords
-
Journal
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Volume 221, Issue -, Pages 173474
Publisher
Elsevier BV
Online
2022-10-14
DOI
10.1016/j.pbb.2022.173474
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Update on GPCR-based targets for the development of novel antidepressants
- (2021) Ioannis Mantas et al. MOLECULAR PSYCHIATRY
- Trial of Psilocybin versus Escitalopram for Depression
- (2021) Robin Carhart-Harris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design, Synthesis, and Pharmacological Characterization of Heterobivalent Ligands for the Putative 5-HT2A/mGlu2 Receptor Complex
- (2020) Christian B. M. Poulie et al. JOURNAL OF MEDICINAL CHEMISTRY
- Interclass GPCR heteromerization affects localization and trafficking
- (2020) Rudy Toneatti et al. Science Signaling
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
- (2020) Alan K. Davis et al. JAMA Psychiatry
- The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia
- (2018) Branden J Stansley et al. CURRENT OPINION IN PHARMACOLOGY
- Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity
- (2018) Mario de la Fuente Revenga et al. NEUROPSYCHOPHARMACOLOGY
- Psychedelics Promote Structural and Functional Neural Plasticity
- (2018) Calvin Ly et al. Cell Reports
- Role of mGlu2 in the 5-HT2A receptor-dependent antipsychotic activity of clozapine in mice
- (2018) Kelsey S. Hideshima et al. PSYCHOPHARMACOLOGY
- Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen
- (2018) Adam L. Halberstadt et al. PSYCHOPHARMACOLOGY
- Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects
- (2017) Daisuke Ibi et al. NATURE NEUROSCIENCE
- In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu 2/3 receptor antagonist
- (2017) Jeffrey M. Witkin et al. NEUROPHARMACOLOGY
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
- (2016) Roland R Griffiths et al. JOURNAL OF PSYCHOPHARMACOLOGY
- mGluR2/3 mechanisms in primate dorsolateral prefrontal cortex: evidence for both presynaptic and postsynaptic actions
- (2016) L E Jin et al. MOLECULAR PSYCHIATRY
- Allosteric signaling through an mGlu2 and 5-HT2Aheteromeric receptor complex and its potential contribution to schizophrenia
- (2016) José L. Moreno et al. Science Signaling
- Allosteric signaling through an mGlu2 and 5-HT2Aheteromeric receptor complex and its potential contribution to schizophrenia
- (2016) José L. Moreno et al. Science Signaling
- Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia
- (2015) Bruce J. Kinon et al. BIOLOGICAL PSYCHIATRY
- Atypical antipsychotics and inverse agonism at 5-HT2 receptors
- (2015) Laura Sullivan et al. CURRENT PHARMACEUTICAL DESIGN
- A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
- (2014) AnnCatherine M Downing et al. BMC Psychiatry
- A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia
- (2013) David H Adams et al. BMC Psychiatry
- Preclinical models of antipsychotic drug action
- (2013) José L. Moreno et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- A serotonin hypothesis of schizophrenia
- (2013) Arnold E. Eggers MEDICAL HYPOTHESES
- Chronic treatment with LY341495 decreases 5-HT2A receptor binding and hallucinogenic effects of LSD in mice
- (2013) José L. Moreno et al. NEUROSCIENCE LETTERS
- Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
- (2013) Virginia L. Stauffer et al. SCHIZOPHRENIA RESEARCH
- Update on Typical and Atypical Antipsychotic Drugs
- (2012) Herbert Y. Meltzer Annual Review of Medicine
- Identification of Three Residues Essential for 5-Hydroxytryptamine 2A-Metabotropic Glutamate 2 (5-HT2A·mGlu2) Receptor Heteromerization and Its Psychoactive Behavioral Function
- (2012) José L. Moreno et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity
- (2012) Mitsumasa Kurita et al. NATURE NEUROSCIENCE
- mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants
- (2012) Shigeyuki Chaki et al. NEUROPHARMACOLOGY
- Serotonin receptor expression along the dorsal-ventral axis of mouse hippocampus
- (2012) K. F. Tanaka et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Toward a New Gold Standard for Early Safety: Automated Temperature-Controlled hERG Test on the PatchLiner®
- (2012) Liudmila Polonchuk Frontiers in Pharmacology
- Neuronal localization of 5-HT2A receptor immunoreactivity in the rat hippocampal region
- (2011) Cristiano Bombardi BRAIN RESEARCH BULLETIN
- Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study
- (2011) Josep Maria Haro et al. BRITISH JOURNAL OF PSYCHIATRY
- Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs
- (2011) Miguel Fribourg et al. CELL
- A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
- (2011) Bruce J. Kinon et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists
- (2011) José L. Moreno et al. NEUROSCIENCE LETTERS
- Interdomain movements in metabotropic glutamate receptor activation
- (2011) S. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease
- (2010) Colleen M. Niswender et al. Annual Review of Pharmacology and Toxicology
- Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia
- (2010) Shigeyuki Chaki EUROPEAN JOURNAL OF PHARMACOLOGY
- Schizophrenia
- (2009) Jim van Os et al. LANCET
- Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions
- (2008) László Szidonya et al. JOURNAL OF ENDOCRINOLOGY
- Identification of a serotonin/glutamate receptor complex implicated in psychosis
- (2008) Javier González-Maeso et al. NATURE
- Metabotropic Glutamate 1 Receptor: Current Concepts and Perspectives
- (2008) F. Ferraguti et al. PHARMACOLOGICAL REVIEWS
- Agonist-directed signaling of the serotonin 2A receptor depends on -arrestin-2 interactions in vivo
- (2008) C. L. Schmid et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions
- (2008) M MILLAN et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Mood disorders: Regulation by metabotropic glutamate receptors
- (2007) Andrzej Pilc et al. BIOCHEMICAL PHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now